AstraZeneca suspends share repurchase programme, Core EPS target in the range of $6.00 and $6.30 unchanged
Monday, 1 October 2012
AstraZeneca today announced that it is suspending share repurchases with immediate effect. During 2012 the company has completed net share repurchases of $2.3 billion in respect of its initial target of $4.5 billion.
AstraZeneca confirms its Core EPS target range for the Full Year 2012 is maintained at $6.00 to $6.30.
Pascal Soriot, Chief Executive Officer, AstraZeneca said: "As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the Board and I complete the company's ongoing annual strategy update."
In line with usual practice, AstraZeneca will update the market on the outlook for 2013 in conjunction with the Full Year 2012 Financial Results announcement in January.
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries UK
Esra Erkal-Paler +44 207 604 8030
Sarah Lindgreen +44 20 7604 8033
Media Enquiries Sweden
Ann-Leena Mikiver +46 8 553 260 20
Investor Enquiries
James Ward-Lilley +44 207 604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Ed Seage +1 302 886 4065 mob: +1 302 373 1361